Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Biological: Sacituzumab Govitecan-hziy (SG)
- Registration Number
- NCT05089734
- Lead Sponsor
- Gilead Sciences
- Brief Summary
The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 603
-
Pathologically documented non-small cell lung cancer (NSCLC) with documented evidence of Stage 4 NSCLC disease at the time of enrollment (based on the American Joint Committee on Cancer, Eighth Edition).
-
Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) results are required. Testing prior to enrollment. Resulting for other actionable genomic alterations is recommended and to be performed as per local standard of care and availability of targeted treatment. For patients with squamous cell carcinoma, EGFR and ALK testing is optional.
-
Must have progressed after platinum-based chemotherapy in combination with anti-PD-1/PD-L1 antibody OR platinum-based chemotherapy and anti-PD-1/PD-L1 antibody (in either order) sequentially.
- No additional treatments are allowed in the recurrent/metastatic setting for individuals with no actionable genomic alterations.
- Individuals with EGFR, ALK, or any other known actionable genomic alterations must have also received treatment with at least 1 locally approved and available tyrosine kinase inhibitor 1(TKI) appropriate to the genomic alteration.
- Documented radiographic disease progression while on or after receiving the most recent treatment regimen for advanced or metastatic NSCLC.
-
Measurable disease based on computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by the investigator in accordance with per RECIST Version 1.1.
-
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 before randomization.
-
Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study drug initiation (hemoglobin ≥ 9 g/dL, absolute neutrophil count ≥ 1500/mm^3, and platelets ≥ 100,000/μL).
-
Adequate hepatic function (bilirubin ≤ 1.5 x upper limit of normal (ULN), aspartate aminotransferase and alanine aminotransferase ≤ 2.5 ULN or ≤ 5 x ULN if known liver metastases, and serum albumin > 3 g/dL).
-
Creatinine clearance of at least 30 mL/min as assessed by the Cockcroft-Gault equation.
-
Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
Key
-
Mixed small-cell lung cancer and NSCLC histology.
-
Positive serum pregnancy test or women who are lactating.
-
Received a prior anticancer biologic agent within 4 weeks prior to enrollment or have received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to enrollment and have not recovered (ie, > Grade 2 is considered not recovered) from adverse events (AEs) at the time of study entry. Individuals participating in observational studies are eligible.
-
Have not recovered (ie, > Grade 2 is considered not recovered) from AEs due to a previously administered agent.
-
Previously received treatment with any of the following:
- Topoisomerase 1 inhibitors. Any agent including an antibody-drug conjugate (ADC) containing a chemotherapeutic agent targeting topoisomerase 1
- Trop-2-targeted therapy
- Docetaxel as monotherapy or in combination with other agents
-
Active second malignancy
-
NSCLC that is eligible for definitive local therapy alone.
-
Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of enrollment, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc); any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (ie, rheumatoid arthritis, Sjogren syndrome, sarcoidosis, etc); or prior pneumonectomy.
-
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
-
Active cardiac disease
-
Active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months of enrollment.
-
Active serious infection requiring antibiotics.
-
Positive HIV-1 or HIV-2 antibody with detectable viral load OR taking medications that may interfere with SN-38 metabolism.
-
Positive for hepatitis B surface antigen. Individuals who test positive for hepatitis B core antibody will require hepatitis B virus DNA by quantitative polymerase chain reaction for confirmation of active disease.
-
Positive hepatitis C antibody and detectable hepatitis C viral load.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Sacituzumab Govitecan-hziy (SG) Sacituzumab Govitecan-hziy (SG) Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle (ie, 2 weekly doses plus 1 week without treatment) until progressive disease (PD), death, unacceptable toxicity, or another treatment discontinuation criterion is met. Docetaxel Docetaxel Participants will receive docetaxel 75 mg/m\^2 on Day 1 of a 21-day cycle (ie, once every 3 weeks) until PD, death, unacceptable toxicity, or another treatment discontinuation criterion is met.
- Primary Outcome Measures
Name Time Method Overall Survival (OS) Up to 24.4 months OS is defined as the time from the date of randomization until the date of death from any cause. OS was estimated using Kaplan-Meier estimate. Participants without documentation of death were censored on the date they were last known to be alive.
- Secondary Outcome Measures
Name Time Method Progression-free Survival (PFS) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Up to 24.4 months PFS is defined as the time from the date of randomization until the date of objective disease progression (PD) or death from any cause, whichever occurs first as assessed by RECIST v.1.1. As per RECIST 1.1, PD was defined as: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum measured while on study (this included the baseline sum if that was the smallest on study), in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or the appearance of of 1 or more new lesions or unequivocal progression of existing non-target lesions. Participants who did not have documented disease progression and did not die were censored at their last tumor assessment date. Kaplan-Meier estimate was used for analysis.
Disease Control Rate (DCR) Assessed by Investigator Per RECIST Version 1.1 Up to 24.4 months DCR was defined as the percentage of participants who achieved a CR, PR,or stable disease(SD)as assessed by RECIST v.1.1. Per RECIST 1.1 CR was disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal;PR was at least 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD,taking as reference the smallest sum LD since the treatment started and persistence of 1 or more nontarget lesion(s).PD was at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum measured while on study (this included the baseline sum if that was the smallest on study),in addition of increase of 20% sum also demonstrate an absolute increase of at least 5 mm or appearance of 1 or more new lesions or unequivocal progression of existing non-target lesions.
Time to First Deterioration in Shortness of Breath Domain as Measured by Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) Up to 24.4 months The NSCLC-SAQ is a participant reported outcome with seven items assessing five symptom concepts of NSCLC: cough, pain, dyspnea, fatigue, and appetite. Each item is rated using a five-point verbal rating scale from "No \<symptom\> At All" to "Very severe \<symptom\>" or from "Never to Always" depending on the item's question structure relative to either intensity or frequency, corresponding to a score of 0 to 4, with total score ranging from 0 to 20. The dyspnea (shortness of breath) item uses a "Never(0) to Always(4)" rating scale with higher score indicating higher frequency of dyspnea. Time to deterioration (TTD) was defined as the time from date of randomization to the first date a participant achieves 2-point deterioration from baseline. For shortness of breath domain, a 1-point or greater worsening from baseline represents a clinically meaningful deterioration. Kaplan-Meier estimate was used for analysis.
Objective Response Rate (ORR) Assessed by Investigator Per RECIST Version 1.1 Up to 24.4 months ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) that was confirmed at least 4 weeks later as assessed by RECIST v.1.1. As per RECIST 1.1 CR was defined as: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR was defined as: At least 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Duration of Response (DOR) Assessed by Investigator Per RECIST Version 1.1 Up to 24.4 months DOR is defined as the time from the first documentation of CR or PR to the earlier of the first documentation of PD or death from any cause (whichever comes first) as assessed by RECIST v. 1.1. As per RECIST 1.1 CR was disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR was at least 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD, and PD was at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum measured while on study (this included the baseline sum if that was the smallest on study), in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or the appearance of of 1 or more new lesions or unequivocal progression of existing non-target lesions. Kaplan-Meier estimate was used for analysis.
Percentage of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) Up to 3.5 years An AE was defined as any untoward medical occurrence in a participants administered a medicinal product that does not necessarily have a causal relationship with this treatment. TEAEs were defined as any AEs that begin or worsen on or after the start of study drug through 30 days after the last dose of the study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0.
Percentage of Participants Who Experienced Grade 3 or 4 Treatment Emergent Laboratory Abnormalities Post-Baseline Up to 3.5 years Blood samples were collected for hematology, serum chemistry, and the laboratory abnormalities were assessed. A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose plus 30 days.The most severe graded abnormality observed post-baseline for each graded test was counted for each participant. Safety as assessed by grading of laboratory values and AEs according to the National Cancer Institutes' Common Terminology Criteria for Adverse Events (NCI CTCAE) covering grades 0-5 (0=Normal, 1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening, 5=Death). The percentage of participants with worst postbaseline grades 3 or 4 will be reported.
Time to First Deterioration in NSCLC-SAQ Total Score Up to 24.4 months The NSCLC-SAQ is a participant reported outcome measure with seven items assessing five symptom concepts of NSCLC: cough, pain, dyspnea, fatigue, and appetite. Each item is rated using a five-point verbal rating scale from "No \<symptom\> At All" to "Very severe \<symptom\>" or from "Never to Always" depending on the item's question structure relative to either intensity or frequency, corresponding to a score of 0 to 4. A total score sums all five domain scores at each visit. If any domain score was missing, the score was not computed. The total score ranges between 0 and 20, with higher scores indicating more severe symptoms. TTD was defined as the time from date of randomization to the first date a participant achieves 2-point deterioration from baseline. For NSCLC-SAQ total score, a 2-point or greater worsening from baseline represents a clinically meaningful deterioration. Kaplan-Meier estimate was used for analysis.
Trial Locations
- Locations (225)
Maryland Oncology Hematology, P.A.
🇺🇸Clinton, Maryland, United States
W.G (Bill) Hefner VAMC
🇺🇸Salisbury, North Carolina, United States
Florida Cancer Specialists
🇺🇸West Palm Beach, Florida, United States
St Vincent's Public Hospital
🇦🇺Darlinghurst, New South Wales, Australia
Sunshine Coast University Private Hospital
🇦🇺Birtinya, Queensland, Australia
Algemeen Ziekenhuis Klina
🇧🇪Brasschaat, Belgium
Az Maria Middelares Ghent
🇧🇪Gent, Belgium
Alaska Oncology and Hematology, LLC.
🇺🇸Anchorage, Alaska, United States
Baptist Health Lexington
🇺🇸Lexington, Kentucky, United States
Illinois Cancer Specialists
🇺🇸Niles, Illinois, United States
Stony Brook Cancer Center
🇺🇸Stony Brook, New York, United States
Broome Oncology, LLC
🇺🇸Johnson City, New York, United States
Park Nicollet Frauenshuh Cancer Center
🇺🇸Saint Paul, Minnesota, United States
Tennessee Oncology, PLLC
🇺🇸Chattanooga, Tennessee, United States
USOR - Texas Oncology - McKinney
🇺🇸McKinney, Texas, United States
Shenandoah Oncology Associates, PC
🇺🇸Winchester, Virginia, United States
Southern Highlands Cancer Centre
🇦🇺Bowral, New South Wales, Australia
Baptist Clinical Research Institute
🇺🇸Memphis, Tennessee, United States
Texas Oncology - Bedford
🇺🇸Bedford, Texas, United States
Texas Oncology Cancer Care and Research Center
🇺🇸McAllen, Texas, United States
Texas Oncology-Plano West
🇺🇸Plano, Texas, United States
Texas Oncology - Denton South
🇺🇸Denton, Texas, United States
ASST Cremona
🇮🇹Cremona, Italy
Universitair Ziekenhuis Antwerpen
🇧🇪Edegem, Belgium
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
🇧🇷Ijui, Brazil
CRIO - Centro Regional Integrado de Oncologia
🇧🇷Fortaleza, Brazil
Royal Victoria Regional Health Centre
🇨🇦Barrie, Canada
AOU Policlinico G Rodlico-Oncologia Medica
🇮🇹Catania, Italy
Required Centre Hospitalier Regional de Rimouski
🇨🇦Rimouski, Canada
Hospital de Clínicas de Porto Alegre - HCPA
🇧🇷Porto Alegre, Brazil
ASST Papa Giovanni XXIII, Oncologia Medica
🇮🇹Bergamo, Italy
ASST Grande Ospedale Metropolitano Niguarda SC Oncologia
🇮🇹Milano, Italy
Fondazione Policlinico Universitario Campus Bio-Medico, UOC Oncologia Medica
🇮🇹Roma, Italy
Sana Klinikum Offenbach, Medizinische Klinik IV fur Hamatologie und internistische Onkologie
🇩🇪Offenbach, Germany
Actualidad Basada en la Investigación del Cáncer
🇲🇽Guadalajara, Mexico
Amphia Hospital
🇳🇱Breda, Netherlands
Hospital Universitario Vall D'Hebron
🇪🇸Barcelona, Spain
Hospital Clinical San Carlos
🇪🇸Madrid, Spain
Japanese Red Cross Wakayama Medical Center
🇯🇵Wakayama, Japan
Yokohama Municipal Citizen's Hospital
🇯🇵Yokohama, Japan
Cryptex Investigación Clínica, S.A. de C.V.
🇲🇽Ciudad de Mexico, Mexico
Instituto Português de Oncologia de Coimbra Francisco Gentil
🇵🇹Coimbra, Portugal
Fundacao Champalimaud
🇵🇹Lisbon, Portugal
Hacettepe Üniversitesi Hastanesi
🇹🇷Ankara, Turkey
Hospital Universitari Dexeus
🇪🇸Barcelona, Spain
Institut Catala d'Oncologia Badalona, ICO Badalona, Hospital Germans Trias i Pujol
🇪🇸Badalona, Spain
East Suffolk and North Essex NHS Foundation Trust
🇬🇧Colchester, United Kingdom
Institut Catala D'Oncologia (ICO L'Hospitalet) Hospital Duran i Reynals
🇪🇸Barcelona, Spain
The Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, United Kingdom
Complejo Hospitalario Universitario A Coruna. Hospital Teresa Herrera
🇪🇸A coruna, Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Spain
Memorial Ankara Hastane
🇹🇷Ankara, Turkey
Institut Catala d'Oncologia de Girona
🇪🇸Girona, Spain
Hospital de Sabadell
🇪🇸Sabadell, Spain
Clinica Universidad de Navarra-Pamplona
🇪🇸Pamplona, Spain
The Christie NHS Foundation
🇬🇧Manchester, United Kingdom
Acibadem Bursa Hastanesi
🇹🇷Bursa, Turkey
St James University Hospital
🇬🇧Leeds, United Kingdom
Trakya Üniversitesi Sağlık Araştırma ve Uygulama Merkezi
🇹🇷Edirne, Turkey
Bagcilar Medipol Mega Universite Hastanesi
🇹🇷Istanbul, Turkey
University Hospital Birmingham NHS Trust, Birmingham Heartlands Hospital
🇬🇧Birmingham, United Kingdom
Leicester Royal Infirmary
🇬🇧Leicester, United Kingdom
FirstHealth Outpatient Cancer Center
🇺🇸Pinehurst, North Carolina, United States
Zangmeister Cancer Center
🇺🇸Columbus, Ohio, United States
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
USOR - Arizona Oncology Associates Tucson - Wilmot
🇺🇸Tucson, Arizona, United States
Beverly Hills Cancer Center
🇺🇸Beverly Hills, California, United States
Florida Cancer Specialists (Administration and Drug Shipment)
🇺🇸Fort Myers, Florida, United States
Woodlands Medical Specialists, PA
🇺🇸Pensacola, Florida, United States
Siouxland Regional Cancer Center dba June E. Nylen Cancer Center
🇺🇸Sioux City, Iowa, United States
Lahey Hospital & Medical Center
🇺🇸Burlington, Massachusetts, United States
Nebraska Hematology - Oncology
🇺🇸Lincoln, Nebraska, United States
Levine Cancer Institute
🇺🇸Charlotte, North Carolina, United States
Texas Oncology - Denison
🇺🇸Denison, Texas, United States
Texas Oncology-Plano East
🇺🇸Plano, Texas, United States
Texas Oncology - Paris
🇺🇸Paris, Texas, United States
University of Wisconsin Clinical Science Center
🇺🇸Madison, Wisconsin, United States
Border Medical Oncology Research Unit
🇦🇺Albury, New South Wales, Australia
Gallipoli Medical Research Foundation
🇦🇺Greenslopes, Queensland, Australia
Flinders Medical centre
🇦🇺Bedford Park, South Australia, Australia
Nucleo de Pesquisa da Rede Sao Camilo-Instituto Brasileiro de controle do cancer-IBC
🇧🇷Sao Paulo, Brazil
A Beneficência Portuguesa de São Paulo
🇧🇷São Paulo, Brazil
William Osler Health System-Brampton Civic Hospital
🇨🇦Brampton, Canada
McGill University Health Centre
🇨🇦Montreal, Canada
Windsor Regional Hospital Cancer Program
🇨🇦Windsor, Canada
Institut Sainte Catherine
🇫🇷Avignon, France
Centre Hospitalier de la Côte Basque
🇫🇷Bayonne, France
APHP-Hopital Ambroise-Pare
🇫🇷Boulogne-Billancourt, France
CHU de CAEN
🇫🇷Caen, France
CHU-Hopital Gabriel Montpied
🇫🇷Clermont Ferrand, France
Centre Francois Baclesse
🇫🇷Calvados, France
Centre Hospitalier de Chauny
🇫🇷Chauny, France
Centre Hospitalier Intercommunal de Creteil
🇫🇷Creteil, France
Centre Hospitalier Annecy Genevois
🇫🇷Epagny Metz-tessy, France
Centre Hospitalier Departemental Vendee
🇫🇷La Roche-sur-Yon, France
Clinique Victor Hugo
🇫🇷Le Mans, France
Hopital Dupuytren (CHU de Limoges)
🇫🇷Limoges cedex, France
Chu Montpellier Hopital Arnaud de Villeneuve
🇫🇷Montpellier, France
CHU de Lille
🇫🇷Lille, France
Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud
🇫🇷Pierre Benite, France
GHR Sud Alsace - Hopital Emile Muller
🇫🇷Mulhouse, France
CHU de Bordeaux Hopital Haut leveque
🇫🇷Pessac, France
Institut Curie
🇫🇷Paris cedex 05, France
Centre Hospitalier Universitaire de Rouen - Hopitel Charles Nicolle
🇫🇷Rouen, France
CHU de Poitiers
🇫🇷Poitiers, France
Institut de Cancérologie de l'Ouest - Paysde Loire (site SAINT HERBLAIN)
🇫🇷saint Herblain, France
Hopital Foch
🇫🇷Saint Herblain, France
CHITS-Hopital Sainte Musse
🇫🇷Toulon cedex, France
Institut Cancérologie Strasbourg Europe
🇫🇷Strasbourg, France
Stadtisches Klinikum Braunschweig gGmbH Medizinische Klinik III Hamatologie und Onkologie
🇩🇪Braunschweig, Germany
Klinikum Esslingen GmbH Klinik fur Kardiologie,Angiologie und Pneumologie
🇩🇪Esslingen, Germany
Asklepios Klinikum Harburg, Thoraxzentrum Hamburg - Lungenabteilung
🇩🇪Hamburg, Germany
Lungenfachklink Immenhausen
🇩🇪Immenhausen, Germany
Onkologische Schwerpunktpraxis Heilbronn
🇩🇪Heilbronn, Germany
Studiengeselischaft Hamato-Onkologie Hamburg
🇩🇪Hamburg, Germany
Klinikum Kassel Klinik Für Hämatologie Onkologie Und Immunologie
🇩🇪Kassel, Germany
Universitatsklinikum Schleswig-Holstein - Campus Lubeck, Medizinische Klinik III (Studienzentrum Pneumologie)
🇩🇪Lubeck, Germany
University Hospital Mannheim, Department of Personalized Medical Oncology with Section Thoracic Oncology
🇩🇪Mannheim, Germany
Asklepios-Fachkliniken Munchen-Gauting, Zentrum fur Pneumologie und Thoraxchirurgie
🇩🇪Munchen-Gauting, Germany
Henry Dunant Hospital Center, 4th Oncology Department
🇬🇷Athens, Greece
Metropolitan General, Oncology department
🇬🇷Cholargos, Greece
General Hospital of Chest Diseases "I Sotiria", 3rd Internal Medicine Department of Athens University - Oncology Unit
🇬🇷Athens, Greece
General Oncology Hospital of Kifisia "Agioi Anargyroi", 2nd Department of Medical Oncology
🇬🇷Nea Kifisia, Greece
University General Hospital of Larissa, Oncology Department-1St Internal Medical Division
🇬🇷Larisa, Greece
Euromedica General Clinic of Thessaloniki
🇬🇷Thessaloniki, Greece
Interbalkan Medical Center of Thessaloniki
🇬🇷Thessaloniki, Greece
Samson Assuta Ashdod University Hospital
🇮🇱Ashdod, Israel
Soroka Medical Center
🇮🇱Beer Seva, Israel
Hadassah University Hospital Ein Kerem
🇮🇱Jerusalem, Israel
Kaplan Medical Center
🇮🇱Rehovot, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
UOC Oncologia
🇮🇹San Giovanni Rotondo, Italy
SC Oncologia -ASST SETTE LAGHI
🇮🇹Varese, Italy
Kansai Medical University Hospital
🇯🇵Hirakata, Japan
Hiroshima University Hospital
🇯🇵Hiroshima, Japan
Nippon Medical School Chiba Hokusoh Hospital
🇯🇵Inzai, Japan
Kagoshima University Hospital
🇯🇵Kagoshima, Japan
National Hospital Organization Iwakuni Clinical Center
🇯🇵Iwakuni, Japan
Kanagawa Prefectural Hospital Organization Kanagawa Cardiovascular and Respiratory Center
🇯🇵Kanagawaken, Japan
Kanazawa University Hospital
🇯🇵Kanazawa, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Koto, Japan
Kurume University Hospital
🇯🇵Kurume, Japan
University Hospital Kyoto Prefectural University of Medicine
🇯🇵Kyoto, Japan
Shikoku Cancer Center
🇯🇵Matsuyama, Japan
Miyagi Cancer Center
🇯🇵Miyagi, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Nagasaki University Hospital
🇯🇵Nagasaki, Japan
National Hospital Organization Nagoya Medical Center
🇯🇵Nagoya, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Kindai University Hospital
🇯🇵Osakasayama-Shi, Japan
Osaka Prefectural Hospital Organization Osaka International Cancer Institute
🇯🇵Osaka, Japan
National Hospital Organization Kinki-Chuo Chest Medical Center
🇯🇵Sakai, Japan
Shizuoka Cancer Center
🇯🇵Sunto-gun, Japan
Kansas City VA Medical Center
🇺🇸Westwood, Kansas, United States
ir Charles Gairdner Hospital
🇦🇺Perth, Western Australia, Australia
Joondalup Health Campus
🇦🇺Joondalup, Western Australia, Australia
Barts Health NHS Trust
🇬🇧London, United Kingdom
Azienda Socio Sanitaria Territoriale (ASST) degli Spedali Civili di Brescia
🇮🇹Brescia, Italy
AOU mater Domini, UOC Oncologia Medica e Oncologia Medica Trazionale
🇮🇹Catanzaro, Italy
Instituto Europeo di Oncologia
🇮🇹Milano, Italy
Fondazione IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
ASST Bergamo Ovest- ospedale di Treviglio-u.o. Oncologia
🇮🇹Treviglio, Italy
Ankara Sehir Hastanesi
🇹🇷Dikimevi- Ankara, Turkey
T.C. Saglik Bakanligi Goztepe Prof. Dr Suleyman Yalcin Sehir Hastanesi
🇹🇷Kadikoy, Turkey
Acibadem Maslak Hastanesi
🇹🇷Sariyer, Turkey
Gazi Universitesi Gazi Hastanesi
🇹🇷Yenimahalle, Turkey
Catatina Pesquisa Clinica - Clinica de Neoplasias Litoral
🇧🇷Itajai, Brazil
Centro de Pesquisas Clinicas da Fundacao Doutor Amaral Carvalho
🇧🇷Jau, Brazil
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa
🇧🇷Porto Alegre, Brazil
Instituto do Câncer do Estado de São Paulo "Octavio Frias de Oliveira" - ICESP
🇧🇷Sao Paolo, Brazil
Froedtert Hospital/Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Shamir Medical Center (Assaf Harofeh)
🇮🇱Tzrifin, Israel
National Hospital Organization Asahikawa Medical Center
🇯🇵Asahikawa, Japan
National Cancer Center Hospital
🇯🇵Chuo, Japan
Fukui Prefectural Hospital
🇯🇵Fukui, Japan
Kobe City Medical Center General Hospital
🇯🇵Hyogo, Japan
Centor Hospital of the National Center for Global Health and Medicine
🇯🇵Shinjuku-Ku, Japan
Tottori University Hospital
🇯🇵Yonago, Japan
Haaglanden Medical Centre
🇳🇱Den Haag, Netherlands
Senhora da Hora
🇵🇹Matosinhos, Portugal
Instituto Portugues de Oncologia do Porto
🇵🇹Porto, Portugal
National Hospital Organization Himeji Medical Center
🇯🇵Hyogo, Japan
Saitama Cancer Center
🇯🇵Kitaadachi-gun, Japan
Tochigi Cancer Center
🇯🇵Utsunomiya, Japan
Panamerican Clinical Research S.A. de C.V
🇲🇽Guadalajara, Mexico
Przychodnia Lekarska Komed Roman Karaszewski
🇵🇱Konin, Poland
Centrum Medyczne Mrukmed
🇵🇱Rzeszáw, Poland
Hospital CUF Porto
🇵🇹Porto, Portugal
Maastricht Universitair Medisch Centrum
🇳🇱Maastricht, Netherlands
Erasmus MC
🇳🇱Rotterrdam, Netherlands
Instytut MSF Sp. z o.o.
🇵🇱Lodz, Poland
Hospital Universitario Cruces
🇪🇸Barakaldo, Spain
Hospital San Pedro de Alcantara
🇪🇸Cáceres, Spain
Hospital Universitario Gregorio Marañón
🇪🇸Madrid, Spain
Hospital Universitario Fundacion Jimenez Dias
🇪🇸Madrid, Spain
Hospital universitario la paz
🇪🇸Madrid, Spain
Hospital Virgen de Valme
🇪🇸Sevilla, Spain
Hospital Regional Universitario de Malaga-Hospital Civil
🇪🇸Malaga, Spain
Hospital Clinicl universitario virgen de la Arrixaca
🇪🇸Murcia, Spain
Hospital universitario Virgen Macarena
🇪🇸Sevilla, Spain
Hospital Universitario la Fe
🇪🇸Valencia, Spain
Centro Hospitalar Universitário Lisboa Norte - Hospital Pulido Valente
🇵🇹Lisboa, Portugal
Ad-Vance Medical Research, LLC
🇵🇷Ponce, Puerto Rico
Pan American Center For Oncology Trials, LLC
🇵🇷San Juan, Puerto Rico
Rocky Mountain Cancer Centers - Aurora
🇺🇸Aurora, Colorado, United States
Hospital Universitario de la Princesa
🇪🇸Madrid, Spain
Hospital Universitario 12 Octubre
🇪🇸Madrid, Spain
National Hospital Organization Osaka Toneyama Medical Center
🇯🇵Toyonaka, Japan
Elisabeth-TweeSteden Ziekenhuis (ETZ)
🇳🇱Tilburg, Netherlands
Muellner Hauptstrabe 48
🇦🇹Salzburg, Austria
Icon Cancer Centre
🇦🇺Hobart, Tasmania, Australia
Monash Health
🇦🇺Clayton, Victoria, Australia
Medizinische Universität Innsbruck, Medizinische Universitat Innsbruck, Universitatsklinik fur Innere Medizin V, Hamatologie und Onkolgie
🇦🇹Innsbruck, Austria
zuniklinikum Salzburg, Landeskrankenhaus, Universitatsklinik fur Innere Medizin III der PMU
🇦🇹Salzburg, Austria
Klinik Floridsdorf, Karl Landsteiner Institute fur Lungenforschung und Pneumologische onkologie (LFPO) Abteilung Fur Innere Medizin un Pneumologie
🇦🇹Vienna, Austria
CHU Ambroise Pare
🇧🇪Mons, Belgium
Algemeen Ziekenhuis Sint-Lucas
🇧🇪Gent, Belgium
Kanagawa Cancer Center
🇯🇵Yokohama, Japan
Marzowiecki Szpital Wojewodzki sw Jana Pawla II Wsiedicach sp. z.o.o Siedickie centrum onkoiogii
🇵🇱Siedlce, Poland
Centro Hospitalar Universitario do Porto
🇵🇹Porto, Portugal
Box Hill Hospital
🇦🇺Box Hill, Victoria, Australia
Cliniques Universitaires Saint-Luc
🇧🇪Brussels, Belgium
Comprehensive Cancer Centers of Nevada
🇺🇸Henderson, Nevada, United States
Peninsula & South Eastern Haematology and Oncology Group
🇦🇺Frankston, Victoria, Australia